Good article, thanks for posting. It is tough...tougher again when it is an Aussie bio
Tougher still when there is still no revenue...
Most like to wait longer, wait for proven model via revenue or licensed to GO (eg half way thru P3 or closer to the end of it etc).
There are some options (different pathways) for us though...finally once they get a sense of what drug we have and what it can do....well, chances of a decent funding package will increase.
My thoughts
research reports and media, page-4080
-
- There are more pages in this discussion • 349 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |